uniQure (NASDAQ:QURE) Given Buy Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of uniQure (NASDAQ:QURE) in a research note published on Monday morning,Benzinga reports. The firm currently has a $70.00 price objective on the biotechnology company’s stock.

Other analysts also recently issued research reports about the stock. Chardan Capital began coverage on shares of uniQure in a research note on Tuesday, April 1st. They set a “buy” rating and a $38.00 price target for the company. Wells Fargo & Company cut their price target on shares of uniQure from $35.00 to $30.00 and set an “equal weight” rating on the stock in a research note on Friday, February 28th. StockNews.com upgraded shares of uniQure to a “sell” rating in a report on Tuesday, March 11th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $24.00 price objective on shares of uniQure in a report on Tuesday, January 21st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, uniQure currently has an average rating of “Moderate Buy” and a consensus price target of $38.80.

uniQure Stock Performance

uniQure stock opened at $13.29 on Monday. uniQure has a 1-year low of $3.73 and a 1-year high of $19.18. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51. The firm has a market capitalization of $718.68 million, a P/E ratio of -2.68 and a beta of 0.42. The company’s 50-day moving average is $11.89 and its 200 day moving average is $11.38.

Insider Transactions at uniQure

In related news, CEO Matthew C. Kapusta sold 28,341 shares of the stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $10.29, for a total value of $291,628.89. Following the completion of the sale, the chief executive officer now owns 651,454 shares of the company’s stock, valued at approximately $6,703,461.66. This trade represents a 4.17 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Christian Klemt sold 10,438 shares of the firm’s stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $10.29, for a total value of $107,407.02. Following the completion of the sale, the chief financial officer now directly owns 217,730 shares of the company’s stock, valued at $2,240,441.70. This trade represents a 4.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 90,830 shares of company stock valued at $961,401 over the last 90 days. Corporate insiders own 4.74% of the company’s stock.

Institutional Trading of uniQure

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Sanders Morris Harris LLC raised its stake in shares of uniQure by 50.0% in the 4th quarter. Sanders Morris Harris LLC now owns 102,104 shares of the biotechnology company’s stock valued at $1,803,000 after acquiring an additional 34,034 shares during the period. Franklin Resources Inc. acquired a new position in uniQure during the 3rd quarter worth approximately $7,360,000. Oppenheimer & Co. Inc. purchased a new position in uniQure in the fourth quarter valued at $320,000. Palumbo Wealth Management LLC acquired a new position in shares of uniQure during the 4th quarter worth about $437,000. Finally, Raymond James Financial Inc. purchased a new position in shares of uniQure in the 4th quarter valued at $1,951,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.